Home > Insider Trading > Filing (0000899243-20-032667)

Filing Details

Accession Number:: 0000899243-20-032667
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-12-03 16:05:08
Reporting Period:: 2020-12-01

Accepted Time:: 2020-12-03 16:05:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609809	Seres Therapeutics Inc.	MCRB	Pharmaceutical Preparations (2834)	274326290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1767321	R. Matthew Henn	C/O Seres Therapeutics, Inc. 200 Sidney Street Cambridge MA 02139	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-12-01	26,000	$0.71	38,000	No	4	M	Direct
Common Stock	Acquisiton	2020-12-01	26,250	$9.89	64,250	No	4	M	Direct
Common Stock	Acquisiton	2020-12-01	27,562	$6.01	91,812	No	4	M	Direct
Common Stock	Disposition	2020-12-01	55,706	$26.56	36,106	No	4	S	Direct
Common Stock	Disposition	2020-12-01	26,265	$27.56	9,841	No	4	S	Direct
Common Stock	Disposition	2020-12-01	9,841	$28.34	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-12-01	26,000	$0.00	26,000	$0.71
Common Stock	Stock Option (Right to Buy)	Disposition	2020-12-01	26,250	$0.00	26,250	$9.89
Common Stock	Stock Option (Right to Buy)	Disposition	2020-12-01	27,562	$0.00	27,562	$6.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2016-09-19	2024-08-06	No	4	M	Direct
3,750		2024-08-06	No	4	M	Direct
45,938		2029-01-24	No	4	M	Direct

Footnotes

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.07 to $27.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.10 to $28.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.145 to $28.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option has vested as to 25% of the shares on January 26, 2018. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter.
The option has vested as to 25% of the shares on January 25, 2020. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter.